Table 3. Incidence of neutropenia and chemotherapy-related adverse events in all chemotherapy cycles according to primary prophylaxis.

Variables		Cycles		p-value
		Primary prophylaxis with pegfilgrastim
		No (n = 642)	Yes (n = 792)
Neutropenia (grade 3)		3 (0.4)	122 (15.4)	< 0.001
Neutropenia (grade 4)		639 (99.5)	550 (69.4)	< 0.001
Recovery from neutropenia (days)		4.15 ± 0.72	1.29 ± 0.89	< 0.001
Febrile neutropenia		232 (36.1)	72 (9.1)	< 0.001
Treatment-related toxicity
	Anemia	22 (3.4)	13 (1.6)	0.029
	Thrombocytopenia	6 (0.9)	39 (4.9)	< 0.001
	Transfusion	40 (6.2)	26 (3.3)	0.008
	AST/ALT elevation	1 (0.1)	3 (0.4)	0.426
	Acute kidney injury	0 (0)	0 (0)
Hospitalization		639 (99.5)	235 (29.7)	< 0.001
Dose reduction		119 (18.5)	16 (2.0)	< 0.001
Treatment delay		11 (1.7)	6 (0.7)	0.096

Data are expressed as number (%) or the median (range).

AST = aspartate transaminase; ALT E= alanine aminotransferase.